NeuBase Therapeutics Inc (NAS:NBSE)
$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 21/100

NeuBase Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2021 / 03:30PM GMT
Release Date Price: $72.2 (+2.85%)
Keay Nakae
Chardan Capital - Analyst

It's my pleasure to introduce our next guest from NeuBase Therapeutics, Chairman and CEO, Dietrich Stephan. The format for this session is a roughly 25 minute fireside chat. (Conference Instructions) So with that Dietrich, welcome. Could you please provide a couple of minutes of introductory comments about NeuBase for investors new to the story?

Dietrich Stephan
NeuBase Therapeutics, Inc. - Chairman & CEO, Founder

Sure, thanks again for having us at your conference this year. It's a real pleasure and always enjoy our conversations. So NeuBase Therapeutics is a genetic medicines company that is focused on drugging the genome to resolve root causality across a number of different diseases. And as you know this is a paradigm shift from the way we have historically developed drugs in our industry, drugging proteins through screening large chemical libraries and hoping that some of those chemicals stick and have the activity that we want without the toxicity and then engaging in what's often referred to as sort of a decade

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot